Leukemia

Top Story

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

Midostaurin extends survival in acute myeloid leukemia with <i>FLT3</i> mutation
June 23, 2017

The addition of midostaurin to standard chemotherapy improved OS and EFS among patients with acute myeloid leukemia and FLT3 mutation, according to results of the RATIFY clinical trial.

Based in part on these results — published in The New England Journal of Medicine in conjunction with the study’s presentation at the European Hematology Association Congress in Madrid — the FDA approved midostaurin (Rydapt, Novartis) as part of combination treatment for adults with newly diagnosed FLT3–positive AML in April.

FDA News

FDA approves Rituxan Hycela subcutaneous injection for blood cancers

June 22, 2017
The FDA approved Rituxan Hycela subcutaneous injection to treat three blood cancers. Rituxan Hycela (Genentech) — a combination of rituximab (Rituxan; Genentech…
In the Journals Plus

Azacitidine-based combination may improve response rate in chronic myelomonocytic leukemia

June 21, 2017
Overall response rate improved with the addition of lenalidomide to azacitidine in patients with chronic myelomonocytic leukemia, according to results from the North…
Meeting NewsVideo

VIDEO: Pembrolizumab may improve response to CAR T-cell therapy in children with ALL

June 20, 2017
CHICAGO — The combination of pembrolizumab and CAR T-cell therapy appeared safe and effective in a subset of patients with acute lymphoblastic leukemia who did not…
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Video
Meeting News

VIDEO: Lenalidomide may be ‘practice changing’ for physicians treating leukemia

December 13, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
In the Journals Plus

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

June 23, 2017
The addition of midostaurin to standard chemotherapy improved OS and EFS among patients with acute myeloid leukemia and FLT3 mutation, according to…

FDA News

FDA approves Rituxan Hycela subcutaneous injection for blood cancers

June 22, 2017
The FDA approved Rituxan Hycela subcutaneous injection to treat three blood cancers. Rituxan Hycela (Genentech) — a combination of rituximab…

In the Journals Plus

Azacitidine-based combination may improve response rate in chronic myelomonocytic leukemia

June 21, 2017
Overall response rate improved with the addition of lenalidomide to azacitidine in patients with chronic myelomonocytic leukemia, according to…

Meeting NewsVideo

VIDEO: Pembrolizumab may improve response to CAR T-cell therapy in children with ALL

June 20, 2017
CHICAGO — The combination of pembrolizumab and CAR T-cell therapy appeared safe and effective in a subset of patients with acute lymphoblastic…

Seattle Genetics halts trial of vadastuximab talirine for acute myeloid leukemia

June 19, 2017
Seattle Genetics discontinued a randomized phase 3 trial designed to evaluate vadastuximab talirine for frontline treatment of elderly patients with…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

Meeting NewsVideo

VIDEO: Addition of ublituximab to ibrutinib effective for high-risk chronic lymphocytic leukemia

June 16, 2017
CHICAGO — The addition of ublituximab to ibrutinib appeared safe and effective for patients with high-risk chronic lymphocytic leukemia…

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

In the Journals

Nearly 1 in 3 people worldwide overweight or obese

June 13, 2017
More than 2 billion children and adults globally were affected by excess weight in 2015, and the percentage of people dying from health conditions…

More Headlines »
Advertisement
Advertisement